LNAI

+ Watchlist + Portfolio

Lunai Bioworks Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.38
52-Week Range: $1.21 – $13.28
Market Cap: $5.89M
P/E (TTM): —
EPS (TTM): -61.36
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -325.46%
Return on Assets: -9.65%
Gross Margin: 100.00%
Operating Margin: -6815.30%
Profit Margin: 0.00%
Current Ratio: 0.19
Debt/Equity: —
Total Debt: $1.41M
Free Cash Flow: $-6.96M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.15M

LNAI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Gross Profit	—	$0.00	$0.00	—
Research & Development	$8.37M	$4.17M	$2.71M	$537.43K
Selling, General & Admin	$14.33M	$15.32M	$24.56M	$17.88M
Operating Expenses	$22.83M	$19.60M	$27.39M	$18.55M
Operating Income	-$22.83M	-$19.60M	-$27.39M	-$18.55M
EBITDA	-$112.94M	-$38.86M	-$85.87M	-$177.15M
Pretax Income	-$113.43M	-$39.68M	-$88.43M	-$178.01M
Income Tax	$34.00	$0.00	—	—
Net Income	-$113.43M	-$39.68M	-$88.43M	-$178.01M
Diluted EPS	-172.80	-56.80	-72.80	-86.40
Diluted Shares	656600	703317	1.22M	2.06M

LNAI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$9.17M	$1.87M	$220.47K	$92.70K
Receivables	—	$0.00	$1.11M	$0.00
Current Assets	$9.57M	$2.57M	$2.00M	$1.05M
Total Assets	$84.63M	$58.30M	$163.13M	$8.23M
Current Liabilities	$6.45M	$11.02M	$30.31M	$29.16M
Long-Term Debt	$4.58M	—	—	—
Total Debt	$7.02M	$5.59M	$3.79M	$10.17M
Total Liabilities	$12.01M	$11.80M	$31.15M	$29.58M
Retained Earnings	-$204.35M	-$244.03M	-$332.46M	-$510.46M
Shareholders' Equity	$72.62M	$46.50M	$131.98M	-$21.35M
Working Capital	$3.11M	-$8.46M	-$28.31M	-$28.11M
Net Debt	—	$2.75M	$2.23M	$9.34M

LNAI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.73M	-$11.77M	-$10.97M	-$7.87M
Capital Expenditure	-$5.16K	-$29.77K	-$70.43K	—
Free Cash Flow	-$15.74M	-$11.80M	-$11.04M	-$7.87M
Depreciation & Amortisation	$123.59K	$113.50K	$121.86K	$129.09K
Stock-Based Compensation	$5.49M	$3.54M	$4.67M	$3.31M
Investing Cash Flow	-$5.16K	-$29.77K	-$1.26M	-$500.00K
Financing Cash Flow	$4.25M	$4.52M	$10.52M	$8.38M
Net Change in Cash	-$11.49M	-$7.29M	-$1.71M	$8.13K

LNAI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$20.94K
Cost of Revenue	$0.00	—	—	—	$0.00
Gross Profit	$0.00	—	—	—	$20.94K
Research & Development	-$94.07K	$80.23K	$24.41K	$45.87K	$15.95K
Selling, General & Admin	$4.22M	$4.00M	$2.41M	$1.77M	$1.42M
Operating Expenses	$4.16M	$4.11M	$2.48M	$1.82M	$1.45M
Operating Income	-$4.16M	-$4.11M	-$2.48M	-$1.82M	-$1.43M
EBITDA	$409.84K	-$126.51M	$2.98M	-$1.67M	-$1.34M
Pretax Income	$189.18K	-$126.73M	$2.82M	-$1.80M	-$1.49M
Net Income	$189.18K	-$126.73M	$2.82M	-$1.80M	-$2.57M
Diluted EPS	0.00	—	1.04	-0.64	-0.80
Diluted Shares	2.05M	—	2.82M	2.94M	3.12M

LNAI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$923.00K	$92.70K	$624.81K	$491.64K	$3.16M
Receivables	$1.09M	$0.00	—	—	—
Current Assets	$3.67M	$1.05M	$800.36K	$514.49K	$3.73M
Total Assets	$117.73M	$8.23M	$6.96M	$6.67M	$9.86M
Current Liabilities	$28.84M	$29.16M	$19.72M	$20.00M	$19.28M
Total Debt	$7.03M	$10.17M	$2.71M	$2.75M	$1.41M
Total Liabilities	$29.34M	$29.58M	$20.00M	$20.22M	$19.41M
Retained Earnings	-$383.73M	-$510.46M	-$507.64M	-$509.44M	-$512.01M
Shareholders' Equity	$88.39M	-$21.35M	-$13.04M	-$13.55M	-$9.55M
Working Capital	-$25.17M	-$28.11M	-$18.92M	-$19.49M	-$15.55M
Net Debt	$5.06M	$9.34M	$1.53M	$1.77M	—

LNAI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.49M	-$1.81M	-$1.35M	-$1.07M	-$1.03M
Free Cash Flow	-$1.49M	-$1.81M	-$1.35M	-$1.07M	-$1.03M
Depreciation & Amortisation	$31.98K	$32.63K	$41.52K	$11.18K	$19.63K
Stock-Based Compensation	$1.50M	$897.81K	$181.31K	$128.82K	$168.99K
Investing Cash Flow	-$1.46M	$964.39K	$544.70K	-$1.24K	$0.00
Financing Cash Flow	$3.58M	$178.36K	$1.34M	$950.00K	$3.70M
Net Change in Cash	$632.40K	-$668.39K	$538.95K	-$122.45K	$2.68M

Market Snapshot

About

Lunai Bioworks Inc. is a biotechnology company focused on developing innovative therapeutic solutions. The company operates in the life sciences sector, working on drug discovery and development programs. Lunai Bioworks applies modern biotechnology techniques to address unmet medical needs. The company is in the development stage and focuses on advancing its pipeline of therapeutic candidates.